Market Access for Biosimilars in the EU – Value Assessment/HTA?

Round table organised by FORUM · Institut für Management GmbH

14 December 2015 in Berlin

Your speakers and attendees of the podium discussion

Dr Anne d'Andon
French National Authority for Health (HAS), FRANCE

Head of Medicine Assessment

Dr Antoni Gilabert
Servei Català de la Salut (CatSalut), SPAIN

Managing Director of Pharmacy and Medicines

Dr Birgitte Klindt Poulsen
The Danish Council for the Use of expensive Hospital Medicines (RADS), DENMARK

Member of the board

Thomas Müller
Federal Joint Committee (G-BA), GERMANY

Head of Pharmaceuticals Department

Janet Robertson MRPharmS
National Institute for Health and Care Excellence (NICE), GREAT BRITAIN

Associate Director – Technology Appraisals, Centre for Health Technology Evaluation

Prof Burkhard Sträter
Sträter Lawyers, GERMANY

Partner

My personal invitation to you

Ladies and Gentlemen

Biosimilars are playing an increasingly important role in the national healthcare systems of the EU. But market access and reimbursement are facing challenges:

- Is there a consensus regarding whether or not HTA assessment is necessary for biosimilars?
- How can a substitution be regulated and potentially also be enforced?

These and further topics will be addressed in an intensive discussion among experts from five national HTA bodies.

May I invite you to join the discussion?

Kind regards

Dr Henriette Wolf-Klein
Department Manager Pharma & Healthcare

Your programme

18h00
Introductory speech:
Market access for biosimilars in Germany – the current challenges and regulatory trends at a glance
Prof Burkhard Sträter

18h30
Market access for biosimilars in the UK, France, Germany, Spain/Catalonia and Denmark

- Market access: chances and challenges
- Value assessment for biosimilars foreseen?
- Substitution regulated?

Impulse presentations and panel discussion with
***Dr Anne d'Andon**, HAS, France*
***Dr Antoni Gilabert**, CatSalut, Spain*
***Dr Birgitte Klindt Poulsen**, RADS, Denmark*
***Thomas Müller**, G-BA, Germany*
***Janet Robertson**, NICE, UK*
***Prof Burkhard Sträter** – Chair of the discussion, Germany*

20h30 Get-together for speakers and participants with a buffet

The Market Access of Biosimilars in Germany Is Also Your Focus?

Then don't miss out on our daytime German conference on 14 December in the same conference hotel.

Further information:
Direct: **http://goo.gl/zzrITW**
or on our webpage **www.forum-institut.de** with the webcode 1512233

Need further information?
I'll be happy to help!

FORUM · Institut für Management GmbH
Dr Henriette Wolf-Klein
Department Manager Pharma & Healthcare
Vangerowstr. 18
69115 Heidelberg

Tel. +49 6221 500 680
Fax +49 6221 500 618
h.wolf-klein@forum-institut.de

Registration under

fax +49 6221 500 618 or via e-mail: h.wolf-klein@forum-institut.de

Yes, I will attend the round table

☐ **Market Access of Biosimilars in the EU – Value Assessment/HTA?**

☐ I am interested in receiving more information on FORUM events an agree that this information be sent to me by e-mail.

Name

Position/Department

Company

Street

Postal Code/City/Country

Tel. No.

E-Mail

Contact person at office

Date/Signature

- **Registration: +49 6221 500-680**
- **Conference-No. 15 12 238**

- **Internet:**

www.forum-institut.com

- **Date/Venue:**

Monday, 14 December 2015 in Berlin
17h30 registration; 18h00 - 20h30 round table
Pullman Berlin Schweizerhof
Budapester Str. 25 · 10787 Berlin
Tel. +49 30 2696-0 · Fax +49 30 2696-1000

- **Fee:**

€ 590.00 (+German VAT) incl. certificate, refreshments and get to-gether.

- **Questions and information:**

Dr Henriette Wolf-Klein · Tel. +49 6221 500-680 · h.wolf-klein@forum-institut.de

- **AGB:**

Our general terms and conditions apply (as of 1 December 2011) and are available upon request. We can send them to you anytime or you can fnd them on the internet at www.forum-institut.de/agb_en